Skip to main content
. 2018 Apr 17;10(3):161–177. doi: 10.1007/s13238-018-0533-8

Figure 7.

Figure 7

Proposed model for the role of inhibition of BCLM by Ponatinib. By using gene signature based drug screen strategy, a series of potential anti-breast cancer lung metastasis (BCLM) drugs were found. Among these drugs, Ponatinib inhibits c-Jun function by repressing mRNA transcription and accelerating degradation of c-Jun protein via ERK/c-Jun signal pathway. Through c-Jun, Ponatinib down regulates 4 BCLM related gene expression, finally inhibits BCLM in mouse models